Standards of measurements in myasthenia gravis.
In 1997, the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America formed a Task Force to develop classification and outcome measures for myasthenia gravis (MG). The goal of the Task Force was to achieve uniformity in recording and reporting clinical trials and outcomes research. The Task Force met frequently over a three-year period, obtained input from national and international experts, and produced a consensus document on recommendations for MG clinical research standards. In this article, the essential elements of the Task Force's recommendations will be summarized. In addition, several other MG measurement tools that are in various stages of development are mentioned.
Barohn
Richard J
RJ
Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA. rbarohn@kumc.edu
D000203:Activities of Daily Living; D002986:Clinical Trials as Topic; D003943:Diagnostic Techniques, Neurological; D006801:Humans; D018763:Muscle Fatigue; D009157:Myasthenia Gravis / Q000145:classification* / Q000453:epidemiology / Q000628:therapy*; D017063:Outcome Assessment, Health Care; D012015:Reference Standards; D012107:Research Design; D012720:Severity of Illness Index